{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:18:39Z","timestamp":1794961119029,"version":"4.9.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.ahj.2026.107626","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:25:49Z","timestamp":1791318349000},"page":"107626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)"],"prefix":"10.1016","volume":"304","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4466-4760","authenticated-orcid":false,"given":"Matthew A.","family":"Cavender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania M.","family":"Jastreboff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Y.Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars-Ole","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silas Hinsch","family":"Gylvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Bonde","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Karenina","family":"Osorto Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel W.","family":"le Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2026.107626_bib0001","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMra1112570","article-title":"A tale of coronary artery disease and myocardial infarction","volume":"366","author":"Nabel","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0002","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.jacc.2025.08.015","article-title":"Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023","volume":"86","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107626_bib0003","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0140-6736(24)01210-8","article-title":"Obesity in adults","volume":"404","author":"Lingvay","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107626_bib0004","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/jch.14661","article-title":"Effect of weight loss on blood pressure changes in overweight patients: a systematic review and meta-analysis","volume":"25","author":"Yang","year":"2023","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.ahj.2026.107626_bib0005","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0140-6736(13)61836-X","article-title":"Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107626_bib0006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified Delphi approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107626_bib0007","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.mayocp.2022.10.013","article-title":"Association of initial and longitudinal changes in C-reactive protein with the risk of cardiovascular disease, cancer, and mortality","volume":"98","author":"Suthahar","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ahj.2026.107626_bib0008","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2025.08.047","article-title":"Inflammation and cardiovascular disease: 2025 ACC Scientific Statement: a report of the American College of Cardiology","volume":"87","author":"Mensah","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2026.107626_bib0009","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ecl.2024.10.006","article-title":"Nutrient-stimulating hormone-based therapies for obesity","volume":"54","author":"Cristancho","year":"2025","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ahj.2026.107626_bib0010","doi-asserted-by":"crossref","first-page":"eabm9609","DOI":"10.1126\/science.abm9609","article-title":"A structural basis for amylin receptor phenotype","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ahj.2026.107626_bib0011","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107626_bib0012","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molmet.2017.11.009","article-title":"Amylin - its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity","volume":"8","author":"Boyle","year":"2018","journal-title":"Mol Metab"},{"key":"10.1016\/j.ahj.2026.107626_bib0013","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107626_bib0014","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00125-017-4289-0","article-title":"Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Kapitza","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2026.107626_bib0015","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0016","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0017","doi-asserted-by":"crossref","first-page":"846","DOI":"10.2337\/dc24-1533","article-title":"Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials","volume":"48","author":"Lee","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2026.107626_bib0018","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0019","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107626_bib0020","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107626_bib0021","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0022","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2502082","article-title":"Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes","volume":"393","author":"Davies","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/HYPERTENSIONAHA.125.26055","article-title":"CagriSema reduces blood pressure in adults with overweight or obesity: REDEFINE 1","volume":"83","author":"Verma","year":"2026","journal-title":"Hypertension"},{"key":"10.1016\/j.ahj.2026.107626_bib0024","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-8587(26)00125-7","article-title":"Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study","volume":"14","author":"Buse","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2026.107626_bib0025","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0026","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0027","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/oby.24332","article-title":"Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial","volume":"33","author":"Lam","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.ahj.2026.107626_bib0028","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0029","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.117.033502","article-title":"2017 cardiovascular and stroke endpoint definitions for clinical trials","volume":"137","author":"Hicks","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107626_bib0030","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Reflection paper on assessment of cardiovascular safety profile of medicinal products. Accessed October 27, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-assessment-cardiovascular-safety-profile-medicinal-products_en.pdf."},{"key":"10.1016\/j.ahj.2026.107626_bib0031","unstructured":"Food and Drug Administration. Guidance for industry on diabetes mellitus \u2014 evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Accessed October 27, 2026. https:\/\/www.federalregister.gov\/documents\/2008\/12\/19\/E8-30086\/guidance-for-industry-on-diabetes-mellitus-evaluating-cardiovascular-risk-in-new-antidiabetic."},{"key":"10.1016\/j.ahj.2026.107626_bib0032","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/bimj.201000239","article-title":"Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests","volume":"53","author":"Bretz","year":"2011","journal-title":"Biom J"},{"key":"10.1016\/j.ahj.2026.107626_bib0033","article-title":"Lipid-lowering treatment patterns and risk of subsequent cardiovascular outcomes in patients with recent coronary revascularization","volume":"25","author":"Gazda","year":"2026","journal-title":"Crit Pathw Cardiol"},{"key":"10.1016\/j.ahj.2026.107626_bib0034","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamainternmed.2025.7774","article-title":"Oral semaglutide and heart failure outcomes in persons with type 2 diabetes: a secondary analysis of the SOUL randomized clinical trial","volume":"186","author":"Pop-Busui","year":"2026","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156463","article-title":"Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis of randomized controlled trials","volume":"175","author":"Karakasis","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.ahj.2026.107626_bib0036","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","article-title":"Once-weekly semaglutide in persons with obesity and knee osteoarthritis","volume":"391","author":"Bliddal","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0037","article-title":"Body composition changes after bariatric surgery or treatment with GLP-1 receptor agonists","volume":"9","author":"Wang","year":"2026","journal-title":"JAMA Netw Open"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2026.107626_bib0038","article-title":"Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial","volume":"45","author":"Colhoun","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2026.107626_bib0039","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107626_bib0040","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.2337\/dc24-0764","article-title":"Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT","volume":"47","author":"Lingvay","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2026.107626_bib0041","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2026.107626_bib0042","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0043","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.125.014069","article-title":"Effect of semaglutide on atrial arrhythmias recurrence following ablation for atrial fibrillation: a prospective study","volume":"18","author":"Guo","year":"2025","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.ahj.2026.107626_bib0044","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0045","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12933-022-01585-7","article-title":"Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials","volume":"21","author":"Mosenzon","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2026.107626_bib0046","article-title":"Impact of oral semaglutide on cardiovascular risk factors in patients with type 2 diabetes and atherosclerotic cardiovascular disease and\/or chronic kidney disease: a SOUL post hoc analysis","volume":"46","author":"Mulvagh","year":"2025","journal-title":"Eur Heart J"},{"issue":"Suppl 1","key":"10.1016\/j.ahj.2026.107626_bib0047","article-title":"Semaglutide, inflammatory markers and cardiovascular outcomes in patients with overweight or obesity in the select trial","volume":"395","author":"Plutzky","year":"2024","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2026.107626_bib0049","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12933-022-01601-w","article-title":"Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes","volume":"21","author":"McGuire","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ahj.2026.107626_bib0050","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2026.107626_bib0051","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1016\/S0140-6736(25)01776-3","article-title":"Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?","volume":"406","author":"Muskiet","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2026.107626_bib0052","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326002887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870326002887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:36:37Z","timestamp":1794958597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870326002887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":51,"alternative-id":["S0002870326002887"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107626","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2026.107626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107626"}}